Intent to Sole Source - X10 VIALS of Floxuridine 500MG vials
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Health, Clinical Center (NIH-CC) has issued a Notice of Intent to sole source X10 VIALS of Floxuridine 500MG vials for injections for patient care. The NIH-CC intends to negotiate with Cardinal Health dba Specialty Pharmaceutical Services (JND Therapeutics). This is not a request for proposal, but interested parties may submit capability statements.
Scope of Requirement
The acquisition is for X10 VIALS of Floxuridine 500MG vials for injection, with a catalog/NDC# of 0143-9270-01. These vials are required for patient care at the NIH Clinical Center in Bethesda, MD. Delivery is needed within five business days of approval.
Contract & Timeline
- Type: Special Notice (Notice of Intent to Sole Source)
- Proposed Contractor: Cardinal Health dba Specialty Pharmaceutical Services (JND Therapeutics)
- Statutory Authority: 41 U.S.C. 253(c)(1) as implemented by FAR 6.302-1 (only one responsible source).
- Estimated Value: $41,770.00
- Set-Aside: None (sole source justification)
- Response Due: June 3, 2026, by 12:00 PM Eastern Standard Time.
- Published: May 20, 2026.
Justification for Sole Source
The justification states that Floxuridine 500mg vials are distributed in the United States only by the proposed contractor, Cardinal Health dba CERONA, dba InteraOncology/JND Therapeutics/Specialty Pharmaceutical services/Cardinal Health 105, LLC. Fair and reasonable pricing was determined based on historic and initial purchase prices from this sole distributor.
Action for Bidders
This is not a Request for Proposal. However, all responsible sources that believe they can provide the required Floxuridine 500MG vials may submit a capability statement. Statements should be emailed to valerie.gregorio@nih.gov with the subject line "NOI-CC-OLAO-26-006059" by the response due date. The Government will consider all responses, but a determination not to compete this requirement is solely at their discretion.